Systemic lupus erythematosus (SLE) is an autoimmune disorder affecting various organ systems with unknown etiology. Interleukin-6 (IL-6) and interferon-alpha (IFN-α) have been shown to have a major role in disease pathogenesis, and they correlate with SLE disease activity, but reports in the literature are conflicting. The present study aims to investigate the significance of IL-6 and IFN-α levels in SLE pathogenesis in an eastern Indian cohort.
Material and Methods
70 SLE patients fulfilled SLICC 2012 criteria, and 40 age- and gender-matched healthy controls (HC) were enrolled. Baseline characteristics along with disease activity were recorded for all patients. Levels of IL-6 and IFN-α were measured by using ELISA. For the meta-analysis, published articles were searched through different databases. Two independent researchers extracted data, and the meta-analysis was performed with CMA v3.1.
Results
The plasma levels of IL-6 and IFN-α in SLE patients were significantly elevated compared to HC (IL-6: p < .0001, IFN-α: p = 0.01). SLEDAI score correlated positively with plasma IL-6 (p < .0001, r = 0.46) and IFN-α levels (p < .0001; r = 0.47). Meta-analysis of previous reports, including our case–control data, revealed higher IL-6 (p < .0001) and IFN-α (p = .005) in SLE patients compared to HC. Furthermore, IL-6 (p < .0001, r = 0.526) and IFN-α (p < .0001; r = 0.371) levels positively correlated with the disease activity.
Conclusion
IL-6 and IFN-α levels are elevated in SLE and they correlate with disease activity. Further studies with a larger sample size in different populations are required to validate our findings.
YenEYSinghRR. Brief report: lupus-an unrecognized leading cause of death in young females: a population-based study using nationwide death certificates, 2000-2015. Arthritis Rheumatol2018; 70: 1251–1255. DOI: 10.1002/art.40512
SuDLLuZMShenMN, et al.Roles of pro- and anti-inflammatory cytokines in the pathogenesis of SLE. J Biomed Biotechnol2012; 2012: 347141. DOI: 10.1155/2012/347141
4.
KatsuyamaTTsokosGCMoultonVR. Aberrant T cell signaling and subsets in systemic Lupus Erythematosus. Front Immunol2018; 9: 1088. DOI: 10.3389/fimmu.2018.01088
5.
UciechowskiPDempkeWCM. Interleukin-6: a masterplayer in the cytokine network. Oncology2020; 98: 131–137. DOI: 10.1159/000505099
6.
LugerTAKrutmannJKirnbauerR, et al.IFN-beta 2/IL-6 augments the activity of human natural killer cells. J Immunol1989; 143: 1206–1209.
RyffelBCarBDGunnH, et al.Interleukin-6 exacerbates glomerulonephritis in (NZB x NZW)F1 mice. Am J Pathol1994; 144: 927–937.
9.
JainSParkGSprouleTJ, et al.Interleukin 6 accelerates mortality by promoting the progression of the systemic lupus erythematosus-like disease of BXSB.Yaa Mice. PLoS One2016; 11: e0153059. DOI: 10.1371/journal.pone.0153059
10.
RipleyBJMGoncalvesBIsenbergDA, et al.Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia. Ann Rheum Dis2005; 64: 849–853. DOI: 10.1136/ard.2004.022681
11.
ChunHYChungJWKimHA, et al.Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol2007; 27: 461–466. DOI: 10.1007/s10875-007-9104-0
12.
SabryASheashaaHEl-HusseiniA, et al.Proinflammatory cytokines (TNF-alpha and IL-6) in Egyptian patients with SLE: its correlation with disease activity. Cytokine2006; 35: 148–153. DOI: 10.1016/j.cyto.2006.07.023
13.
IwanoMDohiKHirataE, et al.Urinary levels of IL-6 in patients with active lupus nephritis. Clin Nephrol1993; 40: 16–21
14.
HirohataSKanaiYMitsuoA, et al.Accuracy of cerebrospinal fluid IL-6 testing for diagnosis of lupus psychosis. A multicenter retrospective study. Clin Rheumatol2009; 28: 1319–1323. DOI: 10.1007/s10067-009-1226-8
15.
BengtssonAASturfeltGTruedssonL, et al.Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus2000; 9: 664–671. DOI: 10.1191/096120300674499064
16.
Dall'eraMCCardarelliPMPrestonBT, et al.Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis2005; 64: 1692–1697. DOI: 10.1136/ard.2004.033753
17.
HooksJJMoutsopoulosHMGeisSA, et al.Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med1979; 301: 5–8. DOI: 10.1056/nejm197907053010102
18.
ThorlaciusGEWahren-HerleniusMRönnblomL. An update on the role of type I interferons in systemic lupus erythematosus and sjögren’s syndrome. Curr Opin Rheumatol2018; 30: 471–481. DOI: 10.1097/bor.0000000000000524
19.
LövgrenTElorantaMLBåveU, et al.Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum2004; 50: 1861–1872. DOI: 10.1002/art.20254
20.
HibbertLPflanzSDe Waal MalefytR, et al.IL-27 and IFN-alpha signal via stat1 and stat3 and induce T-Bet and IL-12Rbeta2 in naive T cells. J Interferon Cytokine Res2003; 23: 513–522. DOI: 10.1089/10799900360708632
21.
JegoGPaluckaAKBlanckJ-P, et al.Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity2003; 19: 225–234. DOI: 10.1016/s1074-7613(03)00208-5
22.
Le BonAEtchartNRossmannC, et al.Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol2003; 4: 1009–1015. DOI: 10.1038/ni978
23.
MorandEFFurieRTanakaY, et al.Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med2020; 382: 211–221. DOI: 10.1056/NEJMoa1912196
24.
PetriMOrbaiAMAlarcónGS, et al.Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum2012; 64: 2677–2686. DOI: 10.1002/art.34473
EggerMDavey SmithGSchneiderM, et al.Bias in meta-analysis detected by a simple, graphical test. Bmj1997; 315: 629–634. DOI: 10.1136/bmj.315.7109.629
27.
MelsenWGBootsmaMCRoversMM, et al.The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses. Clin Microbiol Infect2014; 20: 123–129. DOI: 10.1111/1469-0691.12494
28.
WetterslevJJakobsenJCGluudC. Trial sequential analysis in systematic reviews with meta-analysis. BMC Med Res Methodol2017; 17: 39. DOI: 10.1186/s12874-017-0315-7.
29.
Abdel GalilSMEzzeldinNEl-BoshyME. The role of serum IL-17 and IL-6 as biomarkers of disease activity and predictors of remission in patients with lupus nephritis. Cytokine2015; 76: 280–287. DOI: 10.1016/j.cyto.2015.05.007
30.
CavalcantiASantosRMesquitaZ, et al.Cytokine profile in childhood-onset systemic lupus erythematosus: a cross-sectional and longitudinal study. Braz J Med Biol Res2017; 50: e5738. DOI: 10.1590/1414-431x20175738
31.
EvansMAbdouNI. Anti-interleukin-6 and soluble interleukin-6 receptor in systemic lupus erythematosus. Lupus1994; 3: 161–166. DOI: 10.1177/096120339400300306
32.
FuriniFGiulianiALParlatiME, et al.P2X7 receptor expression in patients with serositis related to systemic lupus erythematosus. Front Pharmacol2019; 10. DOI: 10.3389/fphar.2019.00435
33.
HuSXiaoWKongF, et al.Regulatory T cells and their molecular markers in peripheral blood of the patients with systemic lupus erythematosus. J Huazhong Univ Sci Technolog Med Sci2008; 28: 549–552. DOI: 10.1007/s11596-008-0513-y
34.
HuSXuQXiaoW, et al.The expression of molecular chaperone HSP90 and IL-6 in patients with systemic lupus erythematosus. J Huazhong Univ Sci Technolog Med Sci2006; 26: 664–666. DOI: 10.1007/s11596-006-0609-1
35.
KozoraELaudenslagerMLemieuxA, et al.Inflammatory and hormonal measures predict neuropsychological functioning in systemic lupus erythematosus and rheumatoid arthritis patients. J Int Neuropsychol Soc2001; 7: 745–754. DOI: 10.1017/s1355617701766106
36.
MetsärinneKPNordströmDCKonttinenYT, et al.Plasma interleukin-6 and renin substrate in reactive arthritis, rheumatoid arthritis, and systemic lupus erythematosus. Rheumatol Int1992; 12: 93–96. DOI: 10.1007/bf00290261
37.
RuchakornNNgamjanyapornPSuangtamaiT, et al.Performance of cytokine models in predicting SLE activity. Arthritis Res Ther2019; 21: 287–2019. DOI: 10.1186/s13075-019-2029-1
38.
ShahKLeeWWLeeSH, et al.Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus. Arthritis Res Ther2010; 12: R53. DOI: 10.1186/ar2964
39.
SongLQiuFFanY, et al.Glucocorticoid regulates interleukin-37 in systemic lupus erythematosus. J Clin Immunol2013; 33: 111–117. DOI: 10.1007/s10875-012-9791-z
40.
TalaatRMAlrefaeySABassyouniIH, et al.Genetic polymorphisms of interleukin 6 and interleukin 10 in Egyptian patients with systemic lupus eythematosus. Lupus2016; 25: 255–264. DOI: 10.1177/0961203315615219
41.
ThanadetsuntornCNgamjanyapornPSetthaudomC, et al.The model of circulating immune complexes and interleukin-6 improves the prediction of disease activity in systemic lupus erythematosus. Sci Rep2018; 8: 2620. DOI: 10.1038/s41598-018-20947-4
42.
Wan AsyrafWAMohd ShahrirMSAsrulW, et al.The association between serum prolactin levels and interleukin-6 and systemic lupus erythematosus activity. Reumatismo2018; 70: 241–250. DOI: 10.4081/reumatismo.2018.1075
43.
RipleyBJGoncalvesBIsenbergDA, et al.Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia. Ann Rheum Dis2005; 64: 849–853. DOI: 10.1136/ard.2004.022681
44.
MandalMTripathyRPandaAK, et al.Vitamin D levels in Indian systemic lupus erythematosus patients: association with disease activity index and interferon alpha. Arthritis Res Ther2014; 16: R49. DOI: 10.1186/ar4479
45.
NielsenCTLoodCOstergaardO, et al.Plasma levels of galectin-3-binding protein reflect type I interferon activity and are increased in patients with systemic lupus erythematosus. Lupus Sci Med2014; 1: e000026. DOI: 10.1136/lupus-2014-000026
46.
PostalMSinicatoNAPeliçariKO, et al.Clinical and serological manifestations associated with interferon-α levels in childhood-onset systemic lupus erythematosus. Clinics (Sao Paulo)2012; 67: 157–162. DOI: 10.6061/clinics/2012(02)11
47.
MalaviyaANMisraRBanerjeeS, et al.Systemic lupus erythematosus in North Indian Asians. A prospective analysis of clinical and immunological features. Rheumatol Int1986; 6: 97–101. DOI: 10.1007/bf00270344
48.
PaulBJFassaludeenMNandakumarRMJJIRA. Clinical profile of systemic lupus erythematosus in Northern Kerala. 2003; 11: 94–97.
49.
HirohataSKikuchiH. Role of serum IL-6 in neuropsychiatric systemic lupus erythematosus. ACR Open Rheumatol2021; 3: 42–49. DOI: 10.1002/acr2.11217
50.
TanakaYTummalaR. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials. Mod Rheumatol2021; 31: 1–12. DOI: 10.1080/14397595.2020.1812201
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
